Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) Investor Update: Kaplan Fox Continues to Investigate Potential Securities Fraud
02 déc. 2022 13h10 HE
|
Kaplan Fox & Kilsheimer LLP
NEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is continuing its investigation of claims on behalf of investors in Y-mAbs Therapeutics, Inc....